Searchable abstracts of presentations at key conferences in endocrinology

ea0035oc1.5 | Thyroid clinical | ECE2014

rh-TSH (Thyrogen) aided radioiodine therapy in children and adolescents with DTC

Handkiewicz-Junak Daria , Roskosz Jozef , Gawlik Tomasz , Olczyk Tomasz , Gubala Elzbieta , Kropinska Aleksandra , Hasse-Lazar Kornelia , Jarzab Barbara

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...

ea0070aep923 | Thyroid | ECE2020

Adverse effects of tyrosine kinase inhibitors in advanced thyroid carcinoma – a summary of 10-year experience

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieslik Ewa , Gawlik Tomasz , Olczyk Tomasz , Ledwon Aleksandra , Michalik Barbara , Kropinska Aleksadra , Handkiewicz-Junak Daria , Jarzab Barbara

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

ea0040p6 | (1) | ESEBEC2016

Toxicity of tyrosine kinase inhibitors in the treatment of thyroid cancer – a 10-year experience resume

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieślik Ewa , Handkiewicz-Junak Daria , Gawlik Tomasz , Olczyk Tomasz , Kropińska Aleksandra , Michalik Barbara , Gubała Elżbieta , Jarząb Barbara

Targeted therapy based on tyrosine kinase inhibitors (TKIs) constitutes a new treatment modality in thyroid cancer (TC). Their efficacy in prolongation of progression free survival in comparison to placebo has been documented in phase III studies. However, a problem of their tolerability has recently risen as numerous side effects influencing the quality of life may potentially limit their clinical use. Therefore, we decided to carry out a retrospective analysis of the frequen...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...